Clinical trials: Staphylococcal Infections
Staphylococcal Infection
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
The objective of this trial is 1) to evaluate the safety and clinical acceptability of a 5-day course of mupirocin applied every 8 hours (± 2 hours) to the nares, umbilical and perianal areas of infants residing in the ICU.
- Trial name
- NCT01827358
- Testing
- Mupirocin calcium
- Where
- 6 sites in United States
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Skin and Subcutaneous Tissue Bacterial Infections, Staphylococcus Aureus
Staph Household Intervention for Eradication (SHINE)
The investigators propose a pragmatic comparative effectiveness trial evaluating several decolonization strategies in patients with Staphylococcus aureus infection, their household contacts, and household environmental surfaces.
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections, Staphylococcus Aureus, MRSA - Methicillin Resistant Staphylococcus Aureus Infection
- Trial name
- SHINE (NCT02572791)
- Testing
- Chlorhexidine, Mupirocin, Household cleaning
- Where
- 2 sites in United States
- Volunteers
- 835 people
- Sponsor
- Washington University School of Medicine
Endocarditis, Bacterial, Infective Endocarditis
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
The overall goals of this study are to compare the safety and efficacy of daptomycin monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels of 15 to 20 μg/mL for the treatment of…
- Trial name
- HDSAB (NCT00695903)
- Testing
- daptomycin, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Infectious Disease
Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic
The purpose of this study is to determine the extent to which bacterial growth in the nostrils by S. aureus, a common bacteria that is found in hospital environment, can be reduced by NOZIN® Nasal Sanitizer® antiseptic nasal…
- Trial name
- NCT01861457
- Testing
- Nozin® Nasal Sanitizer®
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Staphylococcus Aureus, MRSA Skin Infections
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
This cluster-randomized prospective study will evaluate the effect of hygiene-based intervention strategies on the incidence of overall SSTI and MRSA-associated SSTI among military trainees.
- Conditions
- Staphylococcus Aureus, MRSA Skin Infections, Staphylococcal Skin Infections
- Trial name
- NCT01105767
- Testing
- Chlorhexidine gluconate, Supplemental training, education and hygiene
- Where
- United States
- Volunteers
- 30,209 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Community-Acquired Staphylococcus Aureus
Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children
The primary purpose of this study is to determine if adding bleach baths to routine ways for prevention of Staph infections is helpful. The amount added is a very weak amount.
- Trial name
- NCT00901316
- Testing
- Routine Measures Group, Bleach Bath Group (Bleach plus routine measures)
- Where
- 2 sites in United States
- Volunteers
- 987 people
- Sponsor
- Baylor College of Medicine
Bacteremia, Staphylococcus Aureus
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to…
- Conditions
- Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph
- Trial name
- diSArm (NCT05184764)
- Testing
- AP-SA02
- Where
- 28 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Abscesses
Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses
Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures.
- Trial name
- NCT00973765
- Testing
- bactrim
- Where
- United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- 59th Medical Wing
Staphylococcal Infections, Surgical Site Infection
Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection
This study looks at the difference between XF-73 and placebo in reducing the carriage of a bacteria S. aureus in the nose before, during and after heart surgery.
- Trial name
- NCT03915470
- Testing
- XF-73
- Where
- 21 sites in United States, Georgia and 1 more
- Volunteers
- 124 people
- Sponsor
- Destiny Pharma Plc
HIV Infections, Staphylococcal Infections
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
This study will prospectively evaluate the prevalence and incidence (over a two year period) of MRSA colonization and infection among HIV-infected military beneficiaries to determine predictors for the development of MRSA…
- Trial name
- MRSA (NCT00631566)
- Testing
- Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%
- Where
- 4 sites in United States
- Volunteers
- 550 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Staphylococcal Infection
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
This study will assess the nasal eradication of SA in healthy subjects following treatment with mupirocin 2% (Bactroban 2% Nasal Ointment) twice daily for 5 days, by means of a broth enriched culture microbial assay.
- Trial name
- NCT02284555
- Testing
- Mupirocin
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc
Staphylococcal Infections
SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of a single dose of Staphylococcus aureus 4 antigen vaccine in Japanese adults aged 20 to <86 years.
- Trial name
- NCT02492958
- Testing
- Staphylococcus aureus 4-antigen vaccine
- Where
- 2 sites in Japan
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Pfizer
Staphylococcal Infections, Yeast Infections
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
This partially-blind, placebo controlled study is a Phase 1b study using an investigational vaccine, NDV-3, directed against Staphylococcus aureus and Candida sp.
- Conditions
- Staphylococcal Infections, Yeast Infections, Candidiasis
- Trial name
- NCT01447407
- Testing
- NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, NDV-3 vaccine without alum ID
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- NovaDigm Therapeutics, Inc.
Staphylococcal Infection
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
The purpose of this clinical trial is to evaluate 2 different antibiotics, drugs that fight bacteria, [clindamycin (CLINDA) and trimethoprim-sulfamethoxazole (TMP-SMX)] and wound care for the outpatient management of…
- Trial name
- NCT00730028
- Testing
- Trimethoprim-sulfamethoxazole, Clindamycin
- Where
- 6 sites in United States
- Volunteers
- 1,310 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staph Aureus Colonization, Staph Aureus Infection
Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial
This trial will test the hypothesis that treating parents of neonates requiring NICU care with intranasal mupirocin and topical chlorhexidine bathing will reduce the spread of S. aureus from parents to neonates.
- Trial name
- TREAT PARENTS (NCT02223520)
- Testing
- Mupirocin and Chlorhexidine
- Where
- 2 sites in United States
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Staphylococcal Infections
Cost-Effectiveness Study Comparing Chlorhexidine Bathing With Active Surveillance Cultures to Prevent Methicillin-resistant Staphylococcus Aureus & Other Hospital Infections
This pilot study in our medical intensive care unit will evaluate the clinical and cost-effectiveness of an active surveillance program for methicillin-resistant Staphylococcus aureus (MRSA), compared to routine daily bathing…
- Trial name
- NCT00779246
- Testing
- Nasal swabs for MRSA culture, Chlorhexidine gluconate, Contact isolation
- Where
- United States
- Volunteers
- 1,518 people
- Sponsor
- Christiana Care Health Services
Pneumonia, Ventilator-associated, Pneumonia, Staphylococcal
Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.
The purpose of this study is the prevention of Staphylococcus aureus pneumonia in mechanically ventilated subjects heavily colonized with S. aureus.
- Trial name
- NCT02940626
- Testing
- ASN100
- Where
- 93 sites in United States, Austria and 14 more
- Volunteers
- 155 people
- Sponsor
- Arsanis, Inc.
Infections, Soft Tissue
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
The study evaluates the safety, immunogenicity, and efficacy of the GSK S. aureus candidate vaccine (GSK3878858A) when administered to two groups: healthy adults (dose-escalation phase) and adults aged 18 to 64 years with a…
- Trial name
- NCT04420221
- Testing
- Sa-5Ag half dose non-adjuvanted, Sa-5Ag full dose non-adjuvanted, Sa-5Ag half dose adjuvanted
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skin Infections, Bacterial
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
- Trial name
- NCT00555061
- Testing
- Retapamulin Ointment, 1%
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline